The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Conference on Retroviruses and Opportunistic Infections 2015
Open accessAbstract
113LB [26] aimed at establishing the virological non-inferiority of the TAF formulation compared to the TDF formulation. The primary endpoint was the proportion of people with a viral load (VL) ≤50 copies/mL at 48 weeks using the FDA snapshot endpoint. Median ages of the two groups were 33 and 35 years, 85% in both groups were men, about 25% black and 19% Hispanic/Latino. Median pre-ART CD4 cell count was 404 cells/mm3 in the TAF arm and 406 cells/mm3 in the TDF arm. Pre-ART viral load was 4.58 log10 copies/mL in both arms. The two arms seemed balanced for all measured characteristics. By 48 weeks from enrolment, 5% stopped treatment in the TAF arm and 8% stopped in the TDF arm. At 48 weeks 92% in the TAF arm and 90% in the TDF arm had a VL ≤50 copies/mL. The difference between arms (2.0%, 95% CI: -0.7%–4.7%) and therefore virological non-inferiority of TAF to TDF in this single-tablet combination given to previously untreated people was established. Resistance profiles for people whose treatment failed also appeared to be similar. Virological response rates did not differ between study arms after stratifying participants by pre-treatment viral load above or below 100,000 copies/mL, baseline CD4 cell count above or below 200 cells/mm3, age above or below 50 years, gender or race (no significant interactions detected). Treatment was generally safe and well tolerated, with no statistical differences in overall drug safety profiles between arms. There were few serious adverse events (8% for TAF vs 7% for TDF) or drug discontinuation for this reason (0.9% for TAF vs 1.5% for TDF) in either group. The most common side effects were diarrhoea (18%), nausea (16%) and headache, all occurring with similar frequency in both groups. Although it was reassuring to see that virological non-inferiority and general safety was established it remained unclear from this first presentation whether TAF was indeed inducing less renal toxicity than TDF, which was the main objective for conducting a non-inferiority trial. These potential concerns were partially addressed in the following Abstract 143LB [27] by Paul Sax and colleagues. In this analysis, pre-specified safety endpoints were serum creatinine, proteinuria, and hip and spine bone mineral density (BMD). Tenofovir levels in plasma were 91% lower with TAF than TDF. But tenofovir levels in cells were four times higher with TAF. At week 48 serum creatinine increased on average by 0.11 mg/dL with TDF versus 0.08 mg/dL with TAF (P<0.001), consequently eGFR fell by an average of 11.2 mL/min with TDF versus 6.6 mL/min with TAF (P<0.001). None of the participants who received TAF and four people receiving TDF (0.5%) left the study because of renal adverse events (two renal failures, one decreased eGFR, one nephropathy). Three people in the TAF arm (0.3%) and four in the TDF arm (0.5%) had hypophosphataemia, and two people in each arm (0.2%) had a grade 2 or greater increase in proteinuria. Nobody in the trial developed proximal tubulopathy. Healthier values of urine protein, albumin and β2-microglobulin through 48 weeks were observed in the TAF compared to the TDF arm (P<0.001). Overall, there was a general sense that TAF might cause less toxicity than TDF. However, despite highly statistical significant differences for some of the parameters the clinical difference appeared to be small and it remains unclear whether the small improvement in safety profile justifies the much higher cost of the new compound (TDF is likely to become generic in the near future). Maturation inhibitor BMS-955176 Max Lataillade from Bristol-Myers Squibb presented findings from a Phase IIa proof-of-concept study evaluating BMS-955176, a second-generation maturation inhibitor (Abstract 114LB) [28]. Maturation inhibitors interfere with protease cleavage of the Gag polyprotein, leading to the release of immature virus particles that cannot complete their lifecycle
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sáez-Cirión, A., Bacchus, C., Hocqueloux, L., Avettand-Fenoel, V., Girault, I., Lecuroux, C., Potard, V., Versmisse, P., Melard, A., Prazuck, T., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003211 · Cited by 1,011
HIV-1 DNA predicts disease progression and post-treatment virological control
Williams, J. P., Hurst, J., Stöhr, W., Robinson, N., Brown, H., Fisher, M., Kinloch, S., Cooper, D., Schechter, M., Tambussi, G., et al. (2014) · eLife · doi:10.7554/elife.03821 · Cited by 293
A Dendritic Cell–Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication
García, F., Climent, N., Guardo, A. C., Gil, C., León, A., Autran, B., Lifson, J. D., Martínez-Picado, J., Dalmau, J., Clotet, B., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004682 · Cited by 220
Short-Course Antiretroviral Therapy in Primary HIV Infection
The SPARTAC Trial Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1110039 · Cited by 216
HIV cure research: a formidable challenge
Ananworanich, J., & Fauci, A. S. (2015) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)31152-3 · Cited by 16
Cited by
Past, present and future: 30 years of HIV research
Barré-Sinoussi, F., Ross, A. L., & Delfraissy, J.-F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3132 · Cited by 332
HIV/AIDS: Screening HIV‐Infected Individuals for Anal Cancer Precursor Lesions: A Systematic Review
Chiao, E. Y., Giordano, T. P., Palefsky, J. M., Tyring, S., & Serag, H. E. (2006) · Clinical Infectious Diseases · doi:10.1086/505219 · Cited by 312
Petroll, A. E., Walsh, J. L., Owczarzak, J. L., McAuliffe, T. L., Bogart, L. M., & Kelly, J. A. (2017) · AIDS and Behavior · doi:10.1007/s10461-016-1625-1 · Cited by 309
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic
Cohen, M. S., Hellmann, N., Levy, J. A., DeCock, K., & Lange, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34706 · Cited by 304
Eradicating HIV-1 infection: seeking to clear a persistent pathogen
Archin, N. M., Sung, J. M., Garrido, C., Soriano-Sarabia, N., & Margolis, D. M. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3352 · Cited by 275
Metadata
- Venue
- Journal of Virus Eradication
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 1
- Issue
- 2
- Pages
- 123-128
- ISSN
- 2055-6640 (ISSN-L)
- OpenAlex
- W4247593499
- Cited by
- 421
- References
- 5
- FWCI
- 22.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Conference on Retroviruses and Opportunistic Infections 2015. https://app.cochat.ai/papers/10.1016/s2055-6640(20)30481-7
- The paper
- Conference on Retroviruses and Opportunistic Infections 2015. (2015). Journal of Virus Eradication. https://doi.org/10.1016/s2055-6640(20)30481-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.